The Editor’s Roundtable: Advances in Stem Cell Therapy for Treatment of Cardiovascular Disease
Okyanos Heart Institute, Freeport, The Bahamas.
Am J Cardiol 2012;110:807–816
Vincent E. Friedewald, MDa,*, Joshua M. Hare, MDb, Leslie W. Miller, MDc, Howard T. Walpole, Jr., MDd, James T. Willerson, MDe, and William C. Roberts, MDf
The first clinical trials of stem cell (SC) treatment for cardiac disease in humans, using autologous bone marrow cell transplantation in patients with severe chronic heart failure (HF), were reported in 2002 (using the intracoronary injection route) and in 2003 (using the intramyocardial injection route).1,2 Since those initial reports, numerous additional clinical SC trials have been conducted in the treatment of cardiac disease, with approximately 30 trials under way in the United States in 2012. In addition to bone marrow– derived hematopoietic SCs, subsequent clinical trials have used mesenchymal SCs, endothelial progenitor cells, skeletal myoblasts, induced pluripotent SCs (and derivatives), and cardiac-resident SCs.3